Related coverage linked through entity extraction aliases.
Jul 24, 2026
In AQP4-positive NMOSD, relapse within 4 weeks of meningococcal vaccination was uncommon (3.3% overall). Findings support vaccination as a generally acceptable prerequisite before C5 inhibitor therapy, with causality still unclear.
Mar 06, 2026
The FDA has accepted Hansa Biopharma's Biologics License Application for imlifidase, a desensitization treatment for highly sensitized adult kidney transplant patients with positive crossmatch against deceased donors, with a PDUFA date of December 19, 2026.
Mar 05, 2026
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
